Gore's initiation of a study to compare the VBX stent graft with metal stenting highlights their commitment to advancing the field of vascular interventions. This study aims to provide valuable insights into the safety and efficacy of different treatment options, ultimately improving patient outcomes. Fast Five hosts Sean Whooley and Chris Newmarker explain the details of the study, including the primary endpoint and how doctors feel about the device and study.


Bioretec's decision to increase production capacity for bioresorbable implants reflects the growing demand for advanced implant technologies and their potential to revolutionize patient care. Hear how the company expanded production and how the implant impacts patients. 

Abbott's recent changes in the executive team, including the appointment of a new CFO, indicate the company's commitment to strategic leadership and its efforts to drive continued growth and innovation. Whooley shares who's out and who's in at the company.

Medtronic's initiation of U.S. shipments of the MiniMed 780G insulin pump system signifies a significant milestone in diabetes management for the company. This next-generation continuous glucose monitoring (CGM) system offers enhanced features and capabilities, empowering individuals with diabetes to better manage their condition. Newmarker and Whooley discuss the diabetes business' success in recent months and what's next in the company's CGM pipeline.

Illumina announced that CEO Francis deSouza has resigned from the DNA sequencing and array-based tech developer. The news comes more than a week after Hologic CEO Stephen MacMillan became non-executive board chair. The Fast Five hosts discuss the exit and who is taking on the CEO role. 

Check out the show notes at MassDevice.com/podcast for links to the stories we discussed in today's episode.

Ver todos los episodios